Granulocyte colony stimulating factor in chronic angina to stimulate neovascularisation: A placebo controlled crossover trial

Heart

Volumn 98, Issue 4, 2012, Pages 282-290

  Chih, Sharon ^a,b   Macdonald, Peter S ^a,b,c   McCrohon, Jane A ^b,c   Ma, David ^b,c   Moore, John ^b,c   Feneley, Michael P ^a,b,c   Law, Matthew ^c   Kovacic, Jason C ^d   Graham, Robert M ^a,b,c  

^a VICTOR CHANG CARDIAC RESEARCH INSTITUTE   (Australia)

^b ST VINCENT S HOSPITAL   (Australia)

^c UNIVERSITY OF NEW SOUTH WALES   (Australia)

^d MOUNT SINAI HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ANGIOPOIETIN 1; C REACTIVE PROTEIN; CD133 ANTIGEN; CD34 ANTIGEN; INTERLEUKIN 8; PLACEBO; PLATELET DERIVED GROWTH FACTOR; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; STROMAL CELL DERIVED FACTOR 1; TROPONIN I; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2;

ADULT; AGED; ANGINA PECTORIS; ANGIOGENESIS; ARTICLE; CARDIOVASCULAR MAGNETIC RESONANCE; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; CROSSOVER PROCEDURE; DISEASE SEVERITY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DOWN REGULATION; DRUG DOSE TITRATION; DRUG EFFECT; DRUG EFFICACY; DRUG FATALITY; ENDOTHELIAL PROGENITOR CELL; EXERCISE TEST; FEMALE; FLOW CYTOMETRY; HEART FAILURE; HEART MUSCLE ISCHEMIA; HEART MUSCLE PERFUSION; HEART PROTECTION; HUMAN; IMMUNOASSAY; LOW DRUG DOSE; MALE; MULTIPLE CYCLE TREATMENT; MUSCULOSKELETAL PAIN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; STEM CELL MOBILIZATION; TREATMENT DURATION; UPREGULATION;

AGED; ANGINA PECTORIS; CHRONIC DISEASE; CORONARY VESSELS; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; EXERCISE TEST; FEMALE; FLOW CYTOMETRY; FOLLOW-UP STUDIES; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; IMMUNOASSAY; MAGNETIC RESONANCE IMAGING, CINE; MALE; MIDDLE AGED; NEOVASCULARIZATION, PHYSIOLOGIC; PROSPECTIVE STUDIES; QUALITY OF LIFE; QUESTIONNAIRES; TREATMENT OUTCOME;

EID: 84863404894     PISSN: 13556037     EISSN: 1468201X     Source Type: Journal    
DOI: 10.1136/heartjnl-2011-300751     Document Type: Article

References (44)

1. Kovacic JC, Muller DW, Graham RM. Actions and therapeutic potential of G-CSF and GM-CSF in cardiovascular disease. J Mol Cell Cardiol 2007;42:19-33. (Pubitemid 44958629)
2. Boyle AJ, Whitbourn R, Schlicht S, et al. Intra-coronary high-dose CD34+ stem cells in patients with chronic ischemic heart disease: a 12-month follow-up. Int J Cardiol 2006;109:21-7.
3. Kovacic JC, Macdonald P, Feneley MP, et al. Safety and efficacy of consecutive cycles of granulocyte-colony stimulating factor, and an intracoronary CD133+ cell infusion in patients with chronic refractory ischemic heart disease: the G-CSF in angina patients with IHD to stimulate neovascularization (GAIN I) trial. Am Heart J 2008;156:954-63.
4. Hill JM, Syed MA, Arai AE, et al. Outcomes and risks of granulocyte colony-stimulating factor in patients with coronary artery disease. J Am Coll Cardiol 2005;46:1643-8. (Pubitemid 41531616)
5. Meier P, Gloekler S, de Marchi SF, et al. Myocardial salvage through coronary collateral growth by granulocyte colony-stimulating factor in chronic coronary artery disease: a controlled randomized trial. Circulation 2009;120:1355-63.
6. Suzuki K, Nagashima K, Arai M, et al. Effect of granulocyte colony-stimulating factor treatment at a low dose but for a long duration in patients with coronary heart disease. Circ J 2006;70:430-7.
7. Wang Y, Tägil K, Ripa RS, et al. Effect of mobilization of bone marrow stem cells by granulocyte colony stimulating factor on clinical symptoms, left ventricular perfusion and function in patients with severe chronic ischemic heart disease. Int J Cardiol 2005;100:477-83.
8. Spertus JA, Winder JA, Dewhurst TA, et al. Development and evaluation of the Seattle Angina Questionnaire: a new functional status measure for coronary artery disease. J Am Coll Cardiol 1995;25:333-41.
9. Martin AJ, Glasziou PP, Simes RJ, et al. Predicting patients' utilities from quality of life items: an improved scoring system for the UBQ-H. Qual Life Res 1998;7:703-11. (Pubitemid 29089250)
10. Chih S, Macdonald PS, Feneley MP, et al. Reproducibility of adenosine stress cardiovascular magnetic resonance in multi-vessel symptomatic coronary artery disease. J Cardiovasc Magn Reson 2010;12:42.
11. Harada M, Qin Y, Takano H, et al. G-CSF prevents cardiac remodeling after myocardial infarction by activating the Jak-Stat pathway in cardiomyocytes. Nat Med 2005;11:305-11. (Pubitemid 40460559)
12. Minatoguchi S, Takemura G, Chen XH, et al. Acceleration of the healing process and myocardial regeneration may be important as a mechanism of improvement of cardiac function and remodeling by postinfarction granulocyte colony-stimulating factor treatment. Circulation 2004;109:2572-80.
13. Orlic D, Kajstura J, Chimenti S, et al. Bone marrow cells regenerate infarcted myocardium. Nature 2001;410:701-5. (Pubitemid 32290358)
14. Ohki Y, Heissig B, Sato Y, et al. Granulocyte colony-stimulating factor promotes neovascularization by releasing vascular endothelial growth factor from neutrophils. FASEB J 2005;19:2005-7. (Pubitemid 41759746)
15. Ohtsuka M, Takano H, Zou Y, et al. Cytokine therapy prevents left ventricular remodeling and dysfunction after myocardial infarction through neovascularization. FASEB J 2004;18:851-3.
16. Case J, Mead LE, Bessler WK, et al. Human CD34+AC133+VEGFR-2+ cells are not endothelial progenitor cells but distinct, primitive hematopoietic progenitors. Exp Hematol 2007;35:1109-18. (Pubitemid 46921310)
17. Mills NL, Tura O, Padfield GJ, et al. Dissociation of phenotypic and functional endothelial progenitor cells in patients undergoing percutaneous coronary intervention. Heart 2009;95:2003-8.
18. Vasa M, Fichtlscherer S, Aicher A, et al. Number and migratory activity of circulating endothelial progenitor cells inversely correlate with risk factors for coronary artery disease. Circ Res 2001;89:e1-7.
19. Hill JM, Zalos G, Halcox JP, et al. Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. N Engl J Med 2003;348:593-600. (Pubitemid 36204953)
20. Heeschen C, Lehmann R, Honold J, et al. Profoundly reduced neovascularization capacity of bone marrow mononuclear cells derived from patients with chronic ischemic heart disease. Circulation 2004;109:1615-22. (Pubitemid 38451717)
21. Honold J, Lehmann R, Heeschen C, et al. Effects of granulocyte colony stimulating factor on functional activities of endothelial progenitor cells in patients with chronic ischemic heart disease. Arterioscler Thromb Vasc Biol 2006;26:2238-43. (Pubitemid 44465717)
22. Dlubek D, Drabczak-Skrzypek D, Lange A. Low CXCR4 membrane expression on CD34+ cells characterizes cells mobilized to blood. Bone Marrow Transplant 2005;37:19-23.
23. Brunner S, Huber BC, Fischer R, et al. G-CSF treatment after myocardial infarction: impact on bone marrow-derived vs cardiac progenitor cells. Exp Hematol 2008;36:695-702.
24. Askari AT, Unzek S, Popovic ZB, et al. Effect of stromal-cell-derived factor 1 on stem-cell homing and tissue regeneration in ischaemic cardiomyopathy. Lancet 2003;362:697-703. (Pubitemid 37101067)
25. Ueda K, Takano H, Hasegawa H, et al. Granulocyte colony stimulating factor directly inhibits myocardial ischemia-reperfusion injury through Akt-endothelial NO synthase pathway. Arterioscler Thromb Vasc Biol 2006;26:e108-13. (Pubitemid 44305355)
26. Kim YJ, Shin JI, Park KW, et al. The effect of granulocyte-colony stimulating factor on endothelial function in patients with myocardial infarction. Heart 2009;95:1320-5.
27. Ridker PM. High-sensitivity C-reactive protein: potential adjunct for global risk assessment in the primary prevention of cardiovascular disease. Circulation 2001;103:1813-18. (Pubitemid 32291421)
28. Ridker PM, Stampfer MJ, Rifai N. Novel risk factors for systemic atherosclerosis: a comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein(a), and standard cholesterol screening as predictors of peripheral arterial disease. JAMA 2001;285:2481-5. (Pubitemid 32433842)
29. Ridker PM, Hennekens CH, Buring JE, et al. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000;342:836-43. (Pubitemid 30165206)
30. Verma S, Wang CH, Li SH, et al. A self-fulfilling prophecy: C-reactive protein attenuates nitric oxide production and inhibits angiogenesis. Circulation 2002;106:913-19. (Pubitemid 34925323)
31. Verma S, Badiwala MV, Weisel RD, et al. C-reactive protein activates the nuclear factor-kappaB signal transduction pathway in saphenous vein endothelial cells: implications for atherosclerosis and restenosis. J Thorac Cardiovasc Surg 2003;126:1886-91. (Pubitemid 38020747)
32. Fujii H, Li SH, Szmitko PE, et al. C-reactive protein alters antioxidant defenses and promotes apoptosis in endothelial progenitor cells. Arterioscler Thromb Vasc Biol 2006;26:2476-82. (Pubitemid 44607468)
33. Verma S, Kuliszewski MA, Li SH, et al. C-reactive protein attenuates endothelial progenitor cell survival, differentiation, and function: further evidence of a mechanistic link between C-reactive protein and cardiovascular disease. Circulation 2004;109:2058-67. (Pubitemid 38620212)
34. Park KW, Kwon YW, Cho HJ, et al. G-CSF exerts dual effects on endothelial cells - Opposing actions of direct eNOS induction versus indirect CRP elevation. J Mol Cell Cardiol 2008;45:670-8.
35. Goetze JP. Biochemistry of pro-B-type natriuretic peptide-derived peptides: the endocrine heart revisited. Clin Chem 2004;50:1503-10. (Pubitemid 39121217)
36. Goetze JP, Christoffersen C, Perko M, et al. Increased cardiac BNP expression associated with myocardial ischemia. FASEB J 2003;17:1105-7.
37. Miller WL, Hartman KA, Burritt MF, et al. Troponin, B-type natriuretic peptides and outcomes in severe heart failure: differences between ischemic and dilated cardiomyopathies. Clin Cardiol 2007;30:245-50. (Pubitemid 46802326)
38. Tsutamoto T, Wada A, Maeda K, et al. Attenuation of compensation of endogenous cardiac natriuretic peptide system in chronic heart failure: prognostic role of plasma brain natriuretic peptide concentration in patients with chronic symptomatic left ventricular dysfunction. Circulation 1997;96:509-16. (Pubitemid 27329427)
39. Heeschen C, Hamm CW, Mitrovic V, et al. N-terminal pro-B-type natriuretic peptide levels for dynamic risk stratification of patients with acute coronary syndromes. Circulation 2004;110:3206-12. (Pubitemid 39525067)
40. de Lemos JA, Morrow DA, Bentley JH, et al. The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes. N Engl J Med 2001;345:1014-21.
41. Omland T, Persson A, Ng L, et al. N-terminal pro-B-type natriuretic peptide and longterm mortality in acute coronary syndromes. Circulation 2002;106:2913-18. (Pubitemid 35424741)
42. Bibbins-Domingo K, Gupta R, Na B, et al. N-terminal fragment of the prohormone brain-type natriuretic peptide (NT-proBNP), cardiovascular events, and mortality in patients with stable coronary heart disease. JAMA 2007;297:169-76. (Pubitemid 46089733)
43. Kragelund C, Gronning B, Kober L, et al. N-terminal pro-B-type natriuretic peptide and long-term mortality in stable coronary heart disease. N Engl J Med 2005;352:666-75. (Pubitemid 40239214)
44. Losordo DW, Schatz RA, White CJ, et al. Intramyocardial transplantation of autologous CD34+ stem cells for intractable angina: a phase I/IIa double-blind, randomized controlled trial. Circulation 2007;115:3165-72. (Pubitemid 47018140)